A Howell

Summary

Affiliation: Christie Hospital
Country: UK

Publications

  1. ncbi request reprint Written report of presented lectures: endocrine treatment and prevention of breast and gynaecological cancers. The scientific basis of endocrine prevention
    A Howell
    CRC Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, UK
    Eur J Cancer 38:S13-4. 2002
  2. ncbi request reprint Faslodex (ICI 182780). an oestrogen receptor downregulator
    A Howell
    CRC Department of Medical Oncology, Christie Hospital NHS Trust, M20 4BX, Manchester, UK
    Eur J Cancer 36:S87-8. 2000
  3. ncbi request reprint Mechanisms of Disease: prediction and prevention of breast cancer--cellular and molecular interactions
    Anthony Howell
    Dept of Medical Oncology, University of Manchester, Christie Hospital, Withington, UK
    Nat Clin Pract Oncol 2:635-46. 2005
  4. ncbi request reprint Pure oestrogen antagonists for the treatment of advanced breast cancer
    Anthony Howell
    CRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester M20 4BX, UK
    Endocr Relat Cancer 13:689-706. 2006
  5. ncbi request reprint Fulvestrant ('Faslodex'): current and future role in breast cancer management
    Anthony Howell
    Cancer Research UK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK
    Crit Rev Oncol Hematol 57:265-73. 2006
  6. ncbi request reprint New developments in the treatment of postmenopausal breast cancer
    Anthony Howell
    CRUK Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Trends Endocrinol Metab 16:420-8. 2005
  7. ncbi request reprint Selective oestrogen receptor downregulator
    Anthony Howell
    CRC Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, UK
    Eur J Cancer 38:S61-2. 2002
  8. ncbi request reprint Adult weight gain and central obesity in women with and without a family history of breast cancer: a case control study
    Michelle N Harvie
    Breast Cancer Prevention Centre, South Manchester University Hospitals NHS Trust, Manchester M20 2LR, UK
    Fam Cancer 6:287-94. 2007
  9. ncbi request reprint Clinical development of fulvestrant ("Faslodex")
    Anthony Howell
    CRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Cancer Treat Rev 31:S3-9. 2005
  10. ncbi request reprint Adjuvant aromatase inhibitors for breast cancer
    Anthony Howell
    CRUK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, M20 4BX, UK
    Lancet 366:431-3. 2005

Collaborators

Detail Information

Publications126 found, 100 shown here

  1. ncbi request reprint Written report of presented lectures: endocrine treatment and prevention of breast and gynaecological cancers. The scientific basis of endocrine prevention
    A Howell
    CRC Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, UK
    Eur J Cancer 38:S13-4. 2002
  2. ncbi request reprint Faslodex (ICI 182780). an oestrogen receptor downregulator
    A Howell
    CRC Department of Medical Oncology, Christie Hospital NHS Trust, M20 4BX, Manchester, UK
    Eur J Cancer 36:S87-8. 2000
    ..In an attempt overcome these negative aspects of tamoxifen therapy, 'pure' anti-oestrogens have been developed and are currently being investigated for the treatment of breast cancer...
  3. ncbi request reprint Mechanisms of Disease: prediction and prevention of breast cancer--cellular and molecular interactions
    Anthony Howell
    Dept of Medical Oncology, University of Manchester, Christie Hospital, Withington, UK
    Nat Clin Pract Oncol 2:635-46. 2005
    ..New approaches are required, however, not only to prevent the disease but to devise methods for their assessment that do not require very large and expensive clinical trials...
  4. ncbi request reprint Pure oestrogen antagonists for the treatment of advanced breast cancer
    Anthony Howell
    CRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester M20 4BX, UK
    Endocr Relat Cancer 13:689-706. 2006
    ..Other similar oestrogen antagonists are undergoing research and development, with a few currently being evaluated in phase II trials...
  5. ncbi request reprint Fulvestrant ('Faslodex'): current and future role in breast cancer management
    Anthony Howell
    Cancer Research UK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK
    Crit Rev Oncol Hematol 57:265-73. 2006
    ..Ongoing trials are investigating the efficacy of fulvestrant after failure on aromatase inhibitors and evaluating its use in combination with therapies that target growth factor receptor signaling pathways...
  6. ncbi request reprint New developments in the treatment of postmenopausal breast cancer
    Anthony Howell
    CRUK Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Trends Endocrinol Metab 16:420-8. 2005
    ..Sequencing options for the future are also discussed because non-steroidal AIs are increasingly used early in the treatment sequence...
  7. ncbi request reprint Selective oestrogen receptor downregulator
    Anthony Howell
    CRC Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, UK
    Eur J Cancer 38:S61-2. 2002
  8. ncbi request reprint Adult weight gain and central obesity in women with and without a family history of breast cancer: a case control study
    Michelle N Harvie
    Breast Cancer Prevention Centre, South Manchester University Hospitals NHS Trust, Manchester M20 2LR, UK
    Fam Cancer 6:287-94. 2007
    ..85; odds ratio (95% CI) = 1.42 (1.01-2.01) (p = 0.044). Significant weight gain between the ages of 20 and 40 and the prevalence of central obesity amongst FH women suggest the need for weight management within FH clinics...
  9. ncbi request reprint Clinical development of fulvestrant ("Faslodex")
    Anthony Howell
    CRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Cancer Treat Rev 31:S3-9. 2005
    ..Further research will define the role of this exciting new agent in the endocrine treatment of breast cancer...
  10. ncbi request reprint Adjuvant aromatase inhibitors for breast cancer
    Anthony Howell
    CRUK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, M20 4BX, UK
    Lancet 366:431-3. 2005
  11. ncbi request reprint A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases
    A Howell
    Cancer Research UK Department of Medical Oncology, Christie CRC Research Hospital, Christie Hospital National Health Service Trust, University of Manchester, Manchester, UK
    Breast Cancer Res Treat 82:215-22. 2003
    ..The results reveal anastrozole to be an effective and valuable first- and second-line therapy in postmenopausal women with ABC and visceral metastases, showing similar CB to other endocrine therapies...
  12. ncbi request reprint Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial
    Anthony Howell
    Christie Hospital and Holt Radium Institute, Manchester, UK
    J Clin Oncol 22:1605-13. 2004
    ....
  13. pmc Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens
    Anthony Howell
    CRUK Department of Medical Oncology, University of Manchester, Christie Hospital, Manchester, UK
    Breast Cancer Res 6:269-74. 2004
    ..Here, we summarize data supporting the difference between the two types of treatment and attempt to account for the underlying mechanisms that favour AIs...
  14. ncbi request reprint Anastrozole: a new gold standard of hormonal treatment for breast cancer?
    Anthony Howell
    CRUK Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester, M20 4BX, UK
    Womens Health (Lond Engl) 1:309-22. 2005
    ..The emergence of aromatase inhibitors as an alternative to tamoxifen for the treatment of breast cancer is challenging the management of the disease and influencing the change of regulatory guidelines...
  15. ncbi request reprint Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    A Howell
    CRC Department of Medical Oncology, Christie Hospital NHS Trust, M20 4BX, Manchester, UK
    J Steroid Biochem Mol Biol 79:227-37. 2001
    ..These data and the newer treatments available indicate a need to re-think our general approach to endocrine therapy and endocrine prevention...
  16. ncbi request reprint New approaches to the endocrine prevention and treatment of breast cancer
    Anthony Howell
    CRUK Department of Medical Oncology, Christie Hospital NHS Trust, University of Manchester, Wilmslow Road, M20 4BX, Manchester, UK
    Cancer Chemother Pharmacol 52:S39-44. 2003
    ..Current and planned endocrine prevention trials in populations of pre- and postmenopausal women at risk of breast cancer are summarized and endocrine therapy after primary surgery and for advanced disease discussed...
  17. ncbi request reprint Preliminary experience with pure antiestrogens
    A Howell
    CRC Department of Medical Oncology, University of Manchester, Christie Hospital, United Kingdom
    Clin Cancer Res 7:4369s-4375s; discussion 4411s-4412s. 2001
    ..Future clinical studies will evaluate fulvestrant in adjuvant and neoadjuvant settings, together with its optimal sequencing in relation to tamoxifen and other endocrine therapies...
  18. ncbi request reprint Energy restriction for breast cancer prevention
    Anthony Howell
    Christie Hospital NHS Trust, University of Manchester, CRUK Department of Medical Oncology, UK
    Recent Results Cancer Res 181:97-111. 2009
    ....
  19. ncbi request reprint Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials
    Anthony Howell
    Department of Medical Oncology, Cancer Research UK, Christie Hospital, Manchester, United Kingdom
    Cancer 104:236-9. 2005
    ..The authors reported the overall survival results from these studies...
  20. ncbi request reprint Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
    A Howell
    Christie Hospital, Manchester, UK
    Lancet 365:60-2. 2005
    ..Anastrozole should be the preferred initial treatment for postmenopausal women with localised hormone-receptor-positive breast cancer...
  21. ncbi request reprint Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
    A Howell
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, United Kingdom
    J Clin Oncol 20:3396-403. 2002
    ..To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) and anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment...
  22. ncbi request reprint Screening younger women with a family history of breast cancer--does early detection improve outcome?
    A Maurice
    Breast Cancer Family History Clinic, Nightingale Centre, Withington Hospital, South Manchester University Hospital Trust, Manchester, UK
    Eur J Cancer 42:1385-90. 2006
    ..These results strongly suggest that screening younger women with a family history of breast cancer leads to improved survival. More precise estimates of the benefit will accrue from further follow-up and other such studies...
  23. ncbi request reprint RASSF1A polymorphism in familial breast cancer
    J Bergqvist
    Genetic Medicine, St Mary s Hospital, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, M13 9WL, UK
    Fam Cancer 9:263-5. 2010
    ..26), BRCA2 (P = 0.16) or BRCA negative (P = 0.30) samples. Hence, the RASSF1A p.A331S polymorphism is not confirmed as a significant germline contributor to familial breast cancer susceptibility...
  24. pmc Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
    M Bramley
    Department of Surgery, Christie Hospital NHS Trust, Manchester M20 4BX, USA
    Br J Cancer 94:1021-8. 2006
    ..We conclude that early anti-oestrogen treatment should prevent breast cancer in very high-risk women...
  25. doi request reprint Risk reducing mastectomy: outcomes in 10 European centres
    D G R Evans
    Central Manchester and Manchester Children s University Hospitals NHS Trust, St Mary s Hospital, Manchester, M13 0JH, UK
    J Med Genet 46:254-8. 2009
    ..Increasingly women at high risk of breast cancer are opting for risk reducing surgery. The aim of this study was to assess the effectiveness of this approach in women at high risk in both carriers and non-carriers of BRCA1/2...
  26. ncbi request reprint Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression
    R B Clarke
    Clinical Research Department, Christie Hospital NHS Trust, Withington, Manchester, UK
    Breast Cancer Res Treat 45:121-33. 1997
    ....
  27. pmc Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy--a longitudinal study
    M N Harvie
    Cancer Research UK Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK
    Br J Cancer 92:673-80. 2005
    ..01) and metastatic breast cancer (Rs=0.617; P<0.05). The ability to meet or exceed energy requirements led to gains in body fat among patients with metastatic breast cancer and NSCLC, but did not prevent loss of FFM in these groups...
  28. ncbi request reprint Breast cancer susceptibility variants alter risk in familial ovarian cancer
    A Latif
    Genetic Medicine, Manchester Academic Heath Science Centre, Central Manchester University Hospitals NHS Foundation Trust, St Mary s Hospital, University of Manchester, Oxford Road, Manchester M13 9WL, UK
    Fam Cancer 9:503-6. 2010
    ..0002). Our results indicate that variants in CASP8 and TNRC9/TOX3 alter the risk of disease in individuals affected with familial ovarian cancer...
  29. ncbi request reprint A protocol for preventative mastectomy in women with an increased lifetime risk of breast cancer
    F Lalloo
    Family History Clinic, Christie NHS Trust, Manchester, UK
    Eur J Surg Oncol 26:711-3. 2000
    ..A time delay is deliberate to allow women to fully address the issues involved with a decision for surgery. Early evidence suggests that this prepares the women emotionally and physically for their surgery...
  30. pmc Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status
    R B Clarke
    Clinical Research Dept, Christie Hospital NHS Trust, Withington, Manchester
    Br J Cancer 67:606-11. 1993
    ..These data indicate that staining with the Ki67 antibody may be useful in monitoring response to anti-oestrogen therapy...
  31. ncbi request reprint Energy balance in early breast cancer patients receiving adjuvant chemotherapy
    Michelle N Harvie
    University Department of Medical Oncology, South Manchester University Hospitals NHS Trust, Manchester, UK
    Breast Cancer Res Treat 83:201-10. 2004
    ..Since weight gain impacts on survival, patients should be counselled to reduce energy intake and exercise during and after adjuvant treatment...
  32. ncbi request reprint Older women with operable breast cancer are less likely to have surgery
    K Lavelle
    School of Nursing, Midwifery and Social Work, University of Manchester, Withington Hospital, Manchester, UK
    Br J Surg 94:1209-15. 2007
    ..Older women are less likely to receive standard management for breast cancer than younger postmenopausal women. Whether differences in general health explain variations in the rates of surgery is not known...
  33. ncbi request reprint A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen
    S R D Johnston
    Cancer Research UK, Lincoln s Inn Fields, London, WC2A 3PX, UK
    Cancer Chemother Pharmacol 53:341-8. 2004
    ....
  34. ncbi request reprint Clinical follow-up after bilateral risk reducing ('prophylactic') mastectomy: mental health and body image outcomes
    P Hopwood
    The CRC Psychological Medicine Group, Christie Hospital NHS Trust, Withington, Manchester, UK
    Psychooncology 9:462-72. 2000
    ..The vast majority of women have breast reconstruction...
  35. ncbi request reprint Future use of selective estrogen receptor modulators and aromatase inhibitors
    A Howell
    CRC Department of Medical Oncology, University of Manchester, Christie Hospital, United Kingdom
    Clin Cancer Res 7:4402s-4410s; discussion 4411s-4412s. 2001
    ..These include alternating and sequential treatments, preferably with treatments changed before overt progression occurs...
  36. ncbi request reprint Investigation of mammary epithelial cell-bone marrow stroma interactions using primary human cell culture as a model of metastasis
    B Brooks
    CRC Department of Experimental Haematology, Paterson Institute for Cancer Research, Manchester, UK
    Int J Cancer 73:690-6. 1997
    ....
  37. ncbi request reprint Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer
    Anthony Howell
    Cancer Research UK, Christie Hospital NHS Trust, University of Manchester, UK
    Clin Breast Cancer 6:302-9. 2005
    ....
  38. ncbi request reprint TPD52 and NFKB1 gene expression levels correlate with G2 chromosomal radiosensitivity in lymphocytes of women with and at risk of hereditary breast cancer
    A H Sims
    Breast Biology Group, Paterson Institute for Cancer Research, University of Manchester, UK
    Int J Radiat Biol 83:409-20. 2007
    ..To evaluate a transcriptomic approach to identify healthy women at increased risk of breast cancer due to G2-radiosensitivity and look at transcripts that are differentially expressed between individuals...
  39. pmc Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer
    A Howell
    CRC Department of Medical Oncology, University of Manchester, Christie Hospital, UK
    Br J Cancer 74:300-8. 1996
    ....
  40. ncbi request reprint Estrogen responsiveness and control of normal human breast proliferation
    E Anderson
    Clinical Research Department, Christie Hospital NHS Trust, Manchester
    J Mammary Gland Biol Neoplasia 3:23-35. 1998
    ..Finally, study of the paracrine mechanisms of growth control in the normal human breast may provide new, more specific, therapeutic targets for breast cancer prevention...
  41. pmc Non-standard management of breast cancer increases with age in the UK: a population based cohort of women > or =65 years
    K Lavelle
    School of Nursing, Midwifery and Social Work, The University of Manchester, Manchester, UK
    Br J Cancer 96:1197-203. 2007
    ..0-61.6). These results demonstrate that older women in the UK are less likely to receive standard management for breast cancer, compared to younger women and this disparity cannot be explained by differences in tumour characteristics...
  42. pmc The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women
    M N Harvie
    Genesis Prevention Centre, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK
    Int J Obes (Lond) 35:714-27. 2011
    ..The problems of adherence to energy restriction in humans are well known...
  43. pmc The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage
    S J Howell
    Department of Medical Oncology, the Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK
    Br J Cancer 101:582-8. 2009
    ..In this study, we report the implementation and screening results from the largest English Cancer Network...
  44. ncbi request reprint Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing
    D G R Evans
    University of Manchester, Central Manchester Foundation Hospital NHS Trust, St Mary s Hospital, Manchester, UK
    J Med Genet 46:811-7. 2009
    ..A number of computer-based models have been developed. However, use of these models can be time consuming and difficult. The Manchester scoring system was developed in 2003 to simplify the selection process without losing accuracy...
  45. ncbi request reprint Surgical decisions made by 158 women with hereditary breast cancer aged <50 years
    D G R Evans
    Academic Unit of Medical Genetics and Regional Genetics Service, St Mary s Hospital, Hathersage Road, Manchester, UK
    Eur J Surg Oncol 31:1112-8. 2005
    ..To establish the uptake of contralateral risk reducing mastectomy in women informed of their risks and options at time of diagnosis of their primary unilateral breast cancer...
  46. pmc The impact of genetic counselling on risk perception in women with a family history of breast cancer
    D G Evans
    CRC Department of Cancer Genetics, Paterson Institute for Cancer Research, Manchester, UK
    Br J Cancer 70:934-8. 1994
    ..Post-counsel women were significantly more likely to retain information if they were sent a post-clinic letter or if they assessed their personal risk as too high initially...
  47. pmc Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone
    R B Clarke
    Clinical Research Department, Christie Hospital NHS Trust, Withington, Manchester, UK
    Br J Cancer 75:251-7. 1997
    ..The results are consistent with the suggestion that E2 may act to stimulate proliferation indirectly via a paracrine mechanism involving IGFs in normal as well as malignant human breast epithelial cells...
  48. ncbi request reprint The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer
    Sacha J Howell
    CRC Department of Medical Oncology, University of Manchester, Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK
    Best Pract Res Clin Endocrinol Metab 18:47-66. 2004
    ..029). Future clinical studies will evaluate fulvestrant in the neoadjuvant setting together with its optimal sequencing in relation to tamoxifen and other endocrine therapies in advanced disease...
  49. ncbi request reprint Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial
    Jack Cuzick
    Centre for Epidemiology, Mathematics, and Statistics, Cancer Research UK, Wolfson Institute of Preventive Medicine, Charterhouse Square, London EC1M 6BQ, UK
    J Natl Cancer Inst 99:272-82. 2007
    ..We report an updated analysis of IBIS-I that focuses on the period after active treatment was completed, a time for which little evidence from other trials is available...
  50. ncbi request reprint Is fulvestrant ("Faslodex") just another selective estrogen receptor modulator?
    A Howell
    Cancer Research UK, Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, United Kingdom
    Int J Gynecol Cancer 16:521-3. 2006
  51. pmc Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires
    P Hopwood
    Cancer Research Campaign Psychological Medicine Group, Christie Hospital and Holt Radium Institute, Withington, Manchester, UK
    Br J Cancer 64:353-6. 1991
    ..Both questionnaires were found to have good predictive value and could be used in patients with advanced cancer to help screen out those with an affective disorder...
  52. pmc High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer
    J E Ferguson
    CRC Department of Medical Oncology, Christie Hospital, Manchester, UK
    Br J Cancer 67:825-9. 1993
    ..The lack of survival benefit and excess toxicity seriously limits the wider application of this regime. It should not be used in place of standard dose palliative chemotherapy for metastatic breast cancer...
  53. pmc Normal human breast xenografts activate N-nitrosodimethylamine: identification of potential target cells for an environmental nitrosamine
    S N Zaidi
    Department of Carcinogenesis, Christie Hospital NHS Trust, Manchester, UK
    Br J Cancer 66:79-83. 1992
    ..Epithelial cells, which are the putative target cells for carcinogenesis in the breast, are therefore prone to promutagenic damage as a result of exposure to an environmental nitrosamine...
  54. ncbi request reprint Breast density and breast cancer risk factors in a high-risk population
    J Warwick
    Department of Mathematics, Statistics and Epidemiology, Cancer Research UK, London WC2A 3PX, UK
    Breast 12:10-6. 2003
    ....
  55. ncbi request reprint Selective oestrogen receptor modulators, aromatase inhibitors and the female breast
    Anthony Howell
    CRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, UK
    Curr Opin Obstet Gynecol 17:429-34. 2005
    ....
  56. ncbi request reprint The endocrine prevention of breast cancer
    Anthony Howell
    CRUK Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, UK
    Best Pract Res Clin Endocrinol Metab 22:615-23. 2008
    ....
  57. ncbi request reprint Fulvestrant (Faslodex): current status in the therapy of breast cancer
    Nigel Bundred
    Academic Department of Surgery, University Hospital of South Manchester, Research and Teaching, Nell Lane, Manchester, M20 2LR, UK
    Expert Rev Anticancer Ther 2:151-60. 2002
    ..Fulvestrant might also have potential as a follow-on therapy after tamoxifen in an adjuvant setting and help alleviate some of the concerns surrounding long-term (up to 5 years) tamoxifen therapy...
  58. pmc The relationship of body weight to response to endocrine therapy, steroid hormone receptors and survival of patients with advanced cancer of the breast
    G Williams
    Department of Surgery, Christie Hospital, Manchester, UK
    Br J Cancer 58:631-4. 1988
    ..Among the patients with operable disease, there was no difference in overall survival (P = 0.42), relapse free survival (P = 0.69), and survival from the start of endocrine therapy (P = 0.85) according to body weight...
  59. ncbi request reprint Acceptability and tolerance of a low tyrosine and phenylalanine diet in patients with advanced cancer -- a pilot study
    Michelle N Harvie
    University Department of Medical Oncology, South Manchester University Hospitals NHS Trust, Manchester, UK
    J Hum Nutr Diet 15:193-202. 2002
    ..Low phenylalanine (phe) and tyrosine (tyr) diets limit tumour growth in animal models and may offer a novel cancer therapy. We studied the efficacy and acceptability of a low phe and tyr diet in patients with advanced cancer...
  60. pmc Cancer experience in the relatives of an unselected series of breast cancer patients
    M D Teare
    Cancer Research Campaign Paediatric and Familial Cancer Research Group, Christie Hospital NHS Trust, Manchester, UK
    Br J Cancer 70:102-11. 1994
    ..These observations may be accounted for by shared environmental factors within families or a common predisposing gene with low penetrance...
  61. ncbi request reprint Energy balance adiposity and breast cancer - energy restriction strategies for breast cancer prevention
    M Harvie
    CRUK University Department of Medical Oncology, Christie Hospital, Manchester, UK
    Obes Rev 7:33-47. 2006
    ..Intermittent energy restriction may be a potential strategy for the primary prevention of breast cancer...
  62. pmc Perception of risk in women with a family history of breast cancer
    D G Evans
    CRC Department of Cancer Genetics, Paterson Institute for Cancer Research, Manchester, UK
    Br J Cancer 67:612-4. 1993
    ..Although it is probable that women are helped by genetic counselling and if at substantial risk, annual mammography, the psychological impact of assigning true risk and the value of mammography need to be evaluated...
  63. pmc Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
    A J Clayton
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK
    Br J Cancer 91:639-43. 2004
    ..HER-2-positive breast cancer may have a predilection for the brain, or trastuzumab therapy may change the disease pattern by prolonging survival. New strategies to address this problem require investigation in this group of patients...
  64. pmc The effect of age and menstrual cycle upon proliferative activity of the normal human breast
    C S Potten
    Department of Epithelial Biology, Paterson Institute for Cancer Research, Manchester, UK
    Br J Cancer 58:163-70. 1988
    ..We conclude that proliferation is negatively related to age and is influenced by the menstrual cycle but that additional as yet unknown factors must account for a large part of the variability seen in the data...
  65. ncbi request reprint Predicting compliance in a breast cancer prevention trial
    Andrew Maurice
    Breast Cancer Family History Clinic, Nightingale Center, Withington Hospital, South Manchester University Hospital Trust, Manchester, UK
    Breast J 12:446-50. 2006
    ..04 and p = 0.047, respectively) and benefit (p = 0.037 and p = 0.031, respectively) to the study. Taking these factors into account when advising women at the start of a chemoprevention trial may be helpful in improving compliance...
  66. ncbi request reprint Overview of the impact of conventional systemic therapies on breast cancer
    Anthony Howell
    CRUK Department of Medical Oncology, University of Manchester, Christie Hospital, 550 Wilmslow Road, Manchester M20 4BX, UK
    Endocr Relat Cancer 12:S9-S16. 2005
    ..It seems likely that herceptin will add to conventional therapies and thus will be the paradigm for the introduction of other biological therapies to improve cure rates...
  67. ncbi request reprint The future of fulvestrant ("Faslodex")
    Anthony Howell
    CRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Cancer Treat Rev 31:S26-33. 2005
    ..The ongoing clinical development programme for fulvestrant will more fully the role of this valuable new agent in the treatment of postmenopausal ABC...
  68. ncbi request reprint Do women understand the odds? Risk perceptions and recall of risk information in women with a family history of breast cancer
    Penelope Hopwood
    Psycho Oncology, Christie Hospital NHS Trust, Manchester, UK
    Community Genet 6:214-23. 2003
    ..To describe and compare women's risk perceptions and recall of breast cancer risk information in a cohort of first-time attendees at a family history clinic...
  69. ncbi request reprint Vascular effects of aromatase inhibitors: data from clinical trials
    Anthony Howell
    CRUK Department of Medical Oncology, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK
    J Steroid Biochem Mol Biol 95:143-9. 2005
    ..At present concerns about deleterious vascular side effects are confined to HRT and SERMs. However, we have few long-term data using AIs for the treatment and prevention of breast cancer...
  70. ncbi request reprint The 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) Trial: a step forward in the treatment of early breast cancer
    Anthony Howell
    CRUK Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK
    Rev Recent Clin Trials 1:207-15. 2006
    ..The ATAC trial provides the most mature data of any AI trial and has enabled the evaluation of a full risk:benefit profile of anastrozole...
  71. ncbi request reprint Are aromatase inhibitors superior to antiestrogens?
    Anthony Howell
    CRUK Department of Medical Oncology, University of Manchester, Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK
    J Steroid Biochem Mol Biol 93:237-47. 2005
    ..Nearly all data available indicate that AIs are superior to tamoxifen. The important question is whether survival is improved when they are used as adjuvant therapy?..
  72. ncbi request reprint Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study
    Valerie Jenkins
    Cancer Research UK, Brighton and Sussex Medical School, University of Sussex, Brighton, UK
    Psychooncology 13:61-6. 2004
    ..In view of the increased use of hormone therapies in an adjuvant and preventative setting their impact on cognitive functioning should be investigated more thoroughly...
  73. pmc An early peak of relapse after surgery for breast cancer
    Anthony Howell
    CRUK Department of Medical Oncology, Christie Hospital, University of Manchester, Manchester, UK
    Breast Cancer Res 6:255-7. 2004
    ..What is now needed is for other groups to repeat this observation and, if found, to examine the characteristics of the tumours producing this phenomenon in order to develop hypotheses about its cause and possible treatments...
  74. pmc The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer
    M H Bronchud
    Cancer Research Campaign Department of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, UK
    Br J Cancer 60:121-5. 1989
    ..Thus the effectiveness of chemotherapy may be enhanced and treatment duration shortened by the use of G-CSF infusions. Further studies of this promising approach are warranted...
  75. pmc Psychiatric morbidity in patients with advanced cancer of the breast: prevalence measured by two self-rating questionnaires
    P Hopwood
    Cancer Research Campaign Psychological Medicine Group, Christie Hospital and Holt Radium Institute, Withington, Manchester, UK
    Br J Cancer 64:349-52. 1991
    ..Only 30 patients (43% of cases) were detected as 'cases' by both questionnaires and this finding warrants further investigation...
  76. ncbi request reprint Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue
    C L Wilson
    Cancer Research UK Bioinformatics Group, Paterson Institute for Cancer Research, Wilmslow Road, Withington, Manchester M20 4BX, UK
    Endocr Relat Cancer 13:617-28. 2006
    ..This suggests that the response to oestrogen in normal breast is highly dependent upon epithelial-stromal/myoepithelial interactions which maintain the tissue microenvironment during epithelial cell proliferation...
  77. ncbi request reprint Macrophage inflammatory protein 1alpha attenuates the toxic effects of temozolomide in human bone marrow granulocyte-macrophage colony-forming cells
    M Clemons
    Cancer Research Campaign Department of Medical Oncology, Manchester, United Kingdom
    Clin Cancer Res 6:966-70. 2000
    ..Whereas the mechanism of this effect remains to be established, the results may have potential immediate clinical application in the attenuation of hematological toxicity after administration of methylating antitumor agents...
  78. pmc Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme
    E Amir
    University of Manchester, UK
    J Med Genet 40:807-14. 2003
    ..A new model by Tyrer and Cuzick has addressed these deficiencies. Therefore, this study has assessed the goodness of fit and discriminatory value of the Tyrer-Cuzick model against established models namely Gail, Claus, and Ford...
  79. ncbi request reprint Origins of breast cancer subtypes and therapeutic implications
    Andrew H Sims
    Breast Biology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK
    Nat Clin Pract Oncol 4:516-25. 2007
    ..Consequently, inhibition of stem-cell self-renewal pathways should be explored because of the likelihood that residual stem cells might be resistant to current therapies...
  80. ncbi request reprint Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study
    Michelle Harvie
    Univeristy Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom
    Cancer Epidemiol Biomarkers Prev 14:656-61. 2005
    ..These data suggest prevention of weight gain between age 18 years and menopause or weight loss and maintenance during these years reduces risk of postmenopausal breast cancer...
  81. ncbi request reprint Estrogen deprivation for breast cancer prevention
    Anthony Howell
    CRUK Department of Medical Oncology, Christie Hospital, University of Manchester, UK
    Recent Results Cancer Res 174:151-67. 2007
    ..It may be possible to increase effectiveness of ED by additional preventive agents or by lifestyle alterations...
  82. doi request reprint Breast cancer susceptibility variants alter risks in familial disease
    Ayse Latif
    Department of Medical Genetics, St Mary s Hospital, Manchester Academic Health Sciences Centre MAHSC, University of Manchester, Manchester M13 0JH, UK
    J Med Genet 47:126-31. 2010
    ..Recent candidate and genome-wide association studies have identified variants altering susceptibility to breast cancer...
  83. doi request reprint Response and resistance to the endocrine prevention of breast cancer
    Anthony Howell
    CRC Department Medical Oncology, University of Manchester Christie Hospital and Holt Radium Inst, Manchester, UK
    Adv Exp Med Biol 617:201-11. 2008
    ....
  84. ncbi request reprint Biomarkers of dietary energy restriction in women at increased risk of breast cancer
    Kai Ren Ong
    Breast Biology Group, School of Cancer and Imaging Sciences, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester M20 4BX, United Kingdom
    Cancer Prev Res (Phila) 2:720-31. 2009
    ..We conclude that reduced expressions of genes in the lipid metabolism and glycolytic pathways are detectable in breast tissue following DER, and these may represent targets for DER mimetics as effective chemoprophylactic agents...
  85. ncbi request reprint Bayesian evaluation of breast cancer screening using data from two studies
    Jonathan P Myles
    Department of Mathematics, Statistics and Epidemiology, Cancer Research UK, London, UK
    Stat Med 22:1661-74. 2003
    ..The method is applied to the synthesis of two studies of mammographic screening in women with a family history of breast cancer, one in Manchester and one in Kopparberg, Sweden...
  86. ncbi request reprint Germline mutation of ARF in a melanoma kindred
    Chelsee Hewitt
    University of Manchester Department of Medical Genetics and Regional Genetic Service, Central Manchester Healthcare Trust, St Mary s Hospital, Manchester, M13 OJH, UK
    Hum Mol Genet 11:1273-9. 2002
    ..Overall, the data suggest a direct role for ARF haploinsufficiency in melanoma predisposition and co-operation between ARF and CDKN2A in tumour formation, consistent with recent observations in Cdkn2a-specific knockout mice...
  87. doi request reprint Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent
    D Gareth R Evans
    Regional Genetic Service, The University of Manchester, St Mary s Hospital, Manchester, United Kingdom
    Cancer Epidemiol Biomarkers Prev 18:2318-24. 2009
    ..We have investigated the rate, timing, and age of uptake of surgery in the northwest of England to report the results after up to 7 years in a Regional Genetics center...
  88. ncbi request reprint Preventing cancer, cardiovascular disease, and diabetes
    Andrew G Renehan
    Department of Surgery, Christie Hospital NHS Trust, Manchester M20 4BX, UK
    Lancet 365:1449-51. 2005
  89. ncbi request reprint Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer
    Mark Clemons
    Department of Medical Oncology, Cancer Research UK, Christie Hospital, Manchester, United Kingdom
    Int J Cancer 103:686-92. 2003
    ..Split-dose DTIC therefore does not appear to be a clinically effective approach to overcome O(6)-alkylating agent resistance in advanced breast cancer...
  90. doi request reprint The origin of estrogen receptor alpha-positive and alpha-negative breast cancer
    Robert B Clarke
    Breast Biology Group, Division of Cancer Studies, University of Manchester Christie Hospital NHS Trust, Manchester, UK
    Adv Exp Med Biol 617:79-86. 2008
  91. pmc Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?
    D Gareth Evans
    Academic Unit of Medical Genetics and Regional Genetics Service, St Mary s Hospital, Manchester, UK
    Breast Cancer Res 6:E7. 2004
    ..Although the high contralateral breast cancer risk is confirmed by this study there is no real evidence for an increase in ipsilateral recurrence or new primary breast cancers in mutation carriers up to the 10-year point...
  92. pmc High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?
    Andrew H Sims
    Breast Biology Group, University of Manchester, Paterson Institute for Cancer Research, Wilmslow Road, Manchester, M20 4BX, UK
    Breast Cancer Res 8:214. 2006
    ..Gene expression profiling is beginning to appear in the breast cancer clinic but it is not yet fully evaluated. This review explores the questions that must be addressed before this technology can become an everyday clinical tool...
  93. pmc Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate
    D J Dodwell
    Department of Medical Oncology, Christie Hospital, Manchester, UK
    Br J Cancer 61:123-5. 1990
    ..Further studies are required in order to determine its value for preventing complications of bone disease and possibly as an adjuvant to surgery for breast cancer...
  94. pmc Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours
    M J Clemons
    Cancer Research UK Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK
    Br J Cancer 86:1797-802. 2002
    ..However, immunohistochemical offers a rapid and convenient method for assessing potential utility of O6-alkylating agents or O6-alkylguanine DNA-alkyltransferase inactivating agents in future studies of breast cancer treatment...
  95. ncbi request reprint Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on
    Andrew G Renehan
    Department of Surgery, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Endocr Relat Cancer 13:273-8. 2006
    ..The reasons are complex and include differences in study design, lack of standardisation between assays, and variations in IGFBP-3 proteolytic activity--these are discussed in this commentary...
  96. ncbi request reprint Normal breast tissue implanted into athymic nude mice identifies biomarkers of the effects of human pregnancy levels of estrogen
    Rognvald N Blance
    Breast Biology Group, School of Cancer and Imaging Sciences, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom
    Cancer Prev Res (Phila) 2:257-64. 2009
    ....
  97. ncbi request reprint Steroid receptors in human breast cancer
    Robert B Clarke
    CR UK Department of Medical Oncology, Christie Hospital, Manchester, UK
    Trends Endocrinol Metab 15:316-23. 2004
    ..These interactions might explain resistance to endocrine treatments and offer solutions in terms of novel therapeutic targets...
  98. ncbi request reprint A putative human breast stem cell population is enriched for steroid receptor-positive cells
    Robert B Clarke
    Breast Biology Group, Cancer Research UK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK
    Dev Biol 277:443-56. 2005
    ..The data suggest a model where scattered steroid receptor-positive cells are stem cells that self-renew through asymmetric cell division and generate patches of transit amplifying and differentiated cells...
  99. ncbi request reprint The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides
    Andrew G Renehan
    Department of Surgery, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Growth Horm IGF Res 17:210-9. 2007
    ..The aim of this study was to clarify these relationships, as circulating IGF-related peptides are potential surrogates of predisposition to common chronic diseases...
  100. ncbi request reprint Lung cancer after treatment for Hodgkin's lymphoma: a systematic review
    Paul Lorigan
    Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK
    Lancet Oncol 6:773-9. 2005
    ..The role of screening in this group of patients has not yet been assessed, but an international study combining CT with genomic and proteomic assessment is planned...
  101. ncbi request reprint Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial
    Lesley Fallowfield
    Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton BN1 9QG, UK
    J Clin Oncol 22:4261-71. 2004
    ..To determine the quality of life (QoL) of women participating in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial during the first 2 years of treatment...